The ultomiris market research report is one of a series of new reports that provides ultomiris market statistics, including ultomiris industry global market size, regional shares, competitors with ultomiris market share, detailed ultomiris market segments, market trends and opportunities, and any further data you may need to thrive in the ultomiris industry. This ultomiris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to increasing burden on healthcare systems, rising incidences of arthritis and inflammatory diseases, rising investments in research, increasing numbers of drug approvals, and increasing prevalence of musculoskeletal disorders. Major trends in the forecast period include advanced hospital infrastructure, advancement in treatment options, strategic research collaborations, development of orphan drugs, and expansion into new indications.
The increasing prevalence of autoimmune conditions is expected to drive the growth of the Ultomiris market. Autoimmune conditions occur when the immune system mistakenly targets and damages the body’s own cells and tissues. This rise in prevalence can be linked to environmental factors such as exposure to pollutants and chemicals, along with advancements in diagnostic methods that have led to more cases being identified and treated. Ultomiris is used to treat autoimmune diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting complement protein C5, which helps reduce immune attacks on the body. For example, a report published by the Australian Institute of Health and Welfare in June 2024 highlighted a 25% increase in hospitalizations for rheumatoid arthritis, an autoimmune condition, from 8,000 in 2021 to 10,000 in 2022, with a hospitalization rate of 39 per 100,000 people. This growing prevalence of autoimmune diseases is contributing to the market expansion of Ultomiris.
Rising healthcare expenditure is anticipated to further boost the growth of the Ultomiris market. Healthcare expenditure refers to the financial resources allocated to medical services, infrastructure, insurance, and related sectors within a country or region. The increase in healthcare spending is driven by factors such as an aging population and the growing prevalence of chronic conditions, which result in higher long-term medical costs. Spending on Ultomiris includes the drug’s cost, its administration, patient monitoring, and ongoing research to expand its potential therapeutic uses. According to a report from the Office for National Statistics in May 2024, healthcare expenditure in the U.S. rose by 5.6% from 2022 to 2023, compared to just 0.9% growth in 2022. As healthcare spending continues to rise, it is expected to support the growth of the Ultomiris market.
A significant trend in the Ultomiris market is the expansion of its therapeutic indications through regulatory approvals. Regulatory approval involves the evaluation and authorization of a new drug by authorities to ensure its safety, efficacy, and quality. For instance, in March 2024, AstraZeneca received approval from the U.S. Food and Drug Administration (FDA) for Ultomiris (ravulizumab-cwvz) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for the anti-aquaporin-4 (AQP4) antibody. This marked a milestone as Ultomiris became the first long-acting C5 complement inhibitor approved for NMOSD, with clinical trials demonstrating a 98.6% reduction in relapse risk. Ultomiris works by inhibiting the complement system to prevent immune attacks on the central nervous system. However, it is associated with risks, including serious meningococcal infections and common side effects such as headaches and urinary tract infections.
The key company operating in the ultomiris market is AstraZeneca Plc.
North America was the largest region in the ultomiris market in 2024. The regions covered in ultomiris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ultomiris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Ultomiris is a prescription medication containing the active ingredient ravulizumab-cwvz, a monoclonal antibody that targets and inhibits C5, a component of the immune system involved in the complement cascade. It is used to treat certain rare and severe autoimmune diseases by preventing the immune system from attacking healthy cells.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for Ultomiris include paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which red blood cells are prematurely destroyed, leading to hemolysis and blood clotting. Ultomiris is available in several formulations, including intravenous solutions and subcutaneous options, and is distributed through hospitals, clinics, and both retail and specialty pharmacies. It serves a variety of end users, including adult and pediatric patients.
The ultomiris market consists of sales of ultomiris injections, alpha-1 proteinase inhibitors, subcutaneous injections, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing burden on healthcare systems, rising incidences of arthritis and inflammatory diseases, rising investments in research, increasing numbers of drug approvals, and increasing prevalence of musculoskeletal disorders. Major trends in the forecast period include advanced hospital infrastructure, advancement in treatment options, strategic research collaborations, development of orphan drugs, and expansion into new indications.
The increasing prevalence of autoimmune conditions is expected to drive the growth of the Ultomiris market. Autoimmune conditions occur when the immune system mistakenly targets and damages the body’s own cells and tissues. This rise in prevalence can be linked to environmental factors such as exposure to pollutants and chemicals, along with advancements in diagnostic methods that have led to more cases being identified and treated. Ultomiris is used to treat autoimmune diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting complement protein C5, which helps reduce immune attacks on the body. For example, a report published by the Australian Institute of Health and Welfare in June 2024 highlighted a 25% increase in hospitalizations for rheumatoid arthritis, an autoimmune condition, from 8,000 in 2021 to 10,000 in 2022, with a hospitalization rate of 39 per 100,000 people. This growing prevalence of autoimmune diseases is contributing to the market expansion of Ultomiris.
Rising healthcare expenditure is anticipated to further boost the growth of the Ultomiris market. Healthcare expenditure refers to the financial resources allocated to medical services, infrastructure, insurance, and related sectors within a country or region. The increase in healthcare spending is driven by factors such as an aging population and the growing prevalence of chronic conditions, which result in higher long-term medical costs. Spending on Ultomiris includes the drug’s cost, its administration, patient monitoring, and ongoing research to expand its potential therapeutic uses. According to a report from the Office for National Statistics in May 2024, healthcare expenditure in the U.S. rose by 5.6% from 2022 to 2023, compared to just 0.9% growth in 2022. As healthcare spending continues to rise, it is expected to support the growth of the Ultomiris market.
A significant trend in the Ultomiris market is the expansion of its therapeutic indications through regulatory approvals. Regulatory approval involves the evaluation and authorization of a new drug by authorities to ensure its safety, efficacy, and quality. For instance, in March 2024, AstraZeneca received approval from the U.S. Food and Drug Administration (FDA) for Ultomiris (ravulizumab-cwvz) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for the anti-aquaporin-4 (AQP4) antibody. This marked a milestone as Ultomiris became the first long-acting C5 complement inhibitor approved for NMOSD, with clinical trials demonstrating a 98.6% reduction in relapse risk. Ultomiris works by inhibiting the complement system to prevent immune attacks on the central nervous system. However, it is associated with risks, including serious meningococcal infections and common side effects such as headaches and urinary tract infections.
The key company operating in the ultomiris market is AstraZeneca Plc.
North America was the largest region in the ultomiris market in 2024. The regions covered in ultomiris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ultomiris market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Ultomiris is a prescription medication containing the active ingredient ravulizumab-cwvz, a monoclonal antibody that targets and inhibits C5, a component of the immune system involved in the complement cascade. It is used to treat certain rare and severe autoimmune diseases by preventing the immune system from attacking healthy cells.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary clinical indications for Ultomiris include paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder in which red blood cells are prematurely destroyed, leading to hemolysis and blood clotting. Ultomiris is available in several formulations, including intravenous solutions and subcutaneous options, and is distributed through hospitals, clinics, and both retail and specialty pharmacies. It serves a variety of end users, including adult and pediatric patients.
The ultomiris market consists of sales of ultomiris injections, alpha-1 proteinase inhibitors, subcutaneous injections, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Ultomiris Market Characteristics4. Ultomiris Market Trends And Strategies5. Ultomiris Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Ultomiris Pricing Analysis & Forecasts30. Global Ultomiris Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Ultomiris Market32. Recent Developments In The Ultomiris Market
3. Ultomiris Market Biologic Drug Characteristics
6. Global Ultomiris Growth Analysis And Strategic Analysis Framework
8. Ultomiris Market Segmentation
9. Global Ultomiris Epidemiology Of Clinical Indications
10. Ultomiris Market Regional And Country Analysis
11. Asia-Pacific Ultomiris Market
12. China Ultomiris Market
13. India Ultomiris Market
14. Japan Ultomiris Market
15. Australia Ultomiris Market
16. South Korea Ultomiris Market
17. Western Europe Ultomiris Market
18. UK Ultomiris Market
19. Germany Ultomiris Market
20. France Ultomiris Market
21. Eastern Europe Ultomiris Market
22. North America Ultomiris Market
23. USA Ultomiris Market
24. Canada Ultomiris Market
25. South America Ultomiris Market
26. Middle East Ultomiris Market
27. Africa Ultomiris Market
28. Ultomiris Market Competitive Landscape And Company Profiles
29. Global Ultomiris Market Pipeline Analysis
33. Ultomiris Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Ultomiris Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on ultomiris market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ultomiris ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ultomiris market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH); Atypical Hemolytic Uremic Syndrome (aHUS); Generalized Myasthenia Gravis (gMG); Neuromyelitis Optica Spectrum Disorder (NMOSD)2) By Formulation: Intravenous Solution; Subcutaneous Formulation
3) By Distribution Channel: Hospital And Clinics; Retail And Specialty Pharmacies
4) By End User: Adult Patients; Pediatric Patients
Key Companies Profiled: AstraZeneca Plc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- AstraZeneca Plc.